Robert Giannini
Principal investigator.
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2010First federal award
$6.5MFederal grants as PI40 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
40 awards · $6.5M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 29, 2023 | NIH | NIH N01 SOCIETAL IS A SMALL BUSINESS CONCERN FOR DOSAGE FORM DEVELOPMENT, MANUFACTURE, AND STABILITY STUDIES OF NCGC72 | $183K | IRISYS, LLC |
| Sep 29, 2023 | NIH | NIH N01 SOCIETAL IS A SMALL BUSINESS CONCERN FOR DOSAGE FORM DEVELOPMENT, MANUFACTURE, AND STABILITY STUDIES OF NCGC72 | $566K | IRISYS, LLC |
| Apr 24, 2023 | NIH | NIH N02 NExT DTP-23-019 GMP PRODUCTION OF 40MG CAPSULES OF Z-ENDOXIFEN | $140K | IRISYS, LLC |
| Apr 18, 2023 | NIH | NIH N02 NEXT DTP-23-017, PRODUCTION OF 0.25MG OF AZATDC AND TDCYD CAPSULES | $66K | IRISYS, LLC |
| Jun 27, 2022 | NIH | NIH N02 NEXT DTP-22-018, GMP PRODUCTION OF 40 MG Z-ENDOXIFEN (NSC 774768) CAPSULES | $190K | IRISYS, LLC |
| Apr 11, 2022 | NIH | NIH N02 NEXT DTP-22-013, PRODUCTION OF TAK-243 INJECTABLE FOR CLINICAL USE | $639K | IRISYS, LLC |
| Mar 8, 2022 | NIH | NIH N01 PRODUCTION OF AMMONIUM TETRATHIOMOLIBDATE (ATTM) CAPSULES FOR USE IN CLINICAL TRIALS | $413K | IRISYS, LLC |
| Nov 19, 2021 | NIH | NIH N01 AZA-TDC CAPSULES FOR USE IN CLINICAL TRIAL | $177K | IRISYS, LLC |
| Sep 25, 2020 | NIH | NIH N01 DOSAGE FORM DEVELOPMENT, MANUFACTURE, AND STABILITY STUDIES OF AVE-1625 (DRINABANT. DRINABANT) IV BAG STUDY | $80K | IRISYS, LLC |
| May 8, 2020 | NIH | NIH N02 PRODUCTION OF VARIOUS STRENGTH OF IPDR CAPSULES FOR CLINICAL USE; POP: 05/08/2020 - 05/07/2021 | $110K | IRISYS, LLC |
| May 8, 2020 | NIH | NIH N02 PRODUCTION OF VARIOUS STRENGTH OF IPDR CAPSULES FOR CLINICAL USE; | $115K | IRISYS, LLC |
| Mar 16, 2020 | NIH | NIH N02 PRODUCTION OF VARIOUS STRENGTH OF AZA-TDC CAPSULES FOR CLINICAL USE POP: 03/16/2020 - 03/15/2021 | $97K | IRISYS, LLC |
| Feb 14, 2020 | NIH | NIH N02 PRODUCTION OF VARIOUS STRENGTH OF INJECTABLE LMP744 FOR CLINICAL USE; POP: 02/14/2020 - 02/13/2021 | $513K | IRISYS, LLC |
| Jan 30, 2020 | NIH | NIH N02 THE PURPOSE OF THIS TASK ORDER IS TO PRODUCE ONE BATCH OF 10,000 ENDOXIFEN CAPSULES, 40 MG PER CAPSULE. (POP: 01/30/2020 TO 06/29/2020) | $100K | IRISYS, LLC |
| May 10, 2019 | NIH | NIH N02 Production of Triapine Injection for Clinical Use | $138K | IRISYS, LLC |
| Apr 17, 2019 | NIH | NIH N02 Production of Aza-TdC Capsules for Clinical Use | $97K | IRISYS, LLC |
| Oct 28, 2018 | NIH | NIH N02 manufacturing four (4) mg Aza-TdC Capsules | $72K | IRISYS, LLC |
| Aug 1, 2018 | NIH | NIH N02 Task Order 27: Study the Stabilizing Effect of StabilOx System on Tetra Thiomolybdate | $30K | IRISYS, LLC |
| Jun 6, 2018 | NIH | NIH N02 Indenos (LMP744, NSC 706744) for Injection | $178K | IRISYS, LLC |
| Nov 16, 2017 | NIH | NIH N02 IGF::OT::IGF PRODUCTION OF 600 BOTTLES OF TETRAHYDROURIDINE POWDER | $73K | IRISYS, LLC |
| Sep 6, 2017 | NIH | NIH N02 IPdR Capsules, 600mg Strength | $81K | IRISYS, LLC |
| Aug 15, 2017 | NIH | NIH N02 Conducting Assay, Purity profile, and Dissolution rate for Decitabine Capsules | $8K | IRISYS, LLC |
| Jun 19, 2017 | NIH | NIH N02 Production and Evaluation of the stability of Tetrathiomolibdate Capsules (Non GMP study) | $18K | IRISYS, LLC |
| Apr 14, 2017 | NIH | NIH N02 IGF::OT::IGF | $83K | IRISYS, LLC |
| Mar 10, 2017 | NIH | NIH N02 IGF::OT:IGF | $77K | IRISYS, LLC |
| Feb 13, 2017 | NIH | NIH N02 Z-Endoxifen HCl Capsules | $240K | IRISYS, LLC |
| Feb 10, 2017 | NIH | NIH N02 IGF::OT::IGF | $179K | IRISYS, LLC |
| Jan 30, 2017 | NIH | NIH N02 BASE AWARD | $83K | IRISYS, LLC |
| Sep 13, 2016 | NIH | NIH N02 IGF::OT::IGF TASK ORDER 15 | $85K | IRISYS, LLC |
| Jul 18, 2016 | NIH | NIH N02 IGF::OT::IGF TASK ORDER 13 | $71K | IRISYS, LLC |
| Jun 10, 2016 | NIH | NIH N02 IGF::OT::IGF 4-THIO-2-DEOXYCYTIDINE, MANUFACTURE A BATCH OF 10 MG STRENGTH CAPSULES UNDER GMP | $60K | IRISYS, LLC |
| Mar 11, 2016 | NIH | NIH N02 IGF::OT::IGF SPECIAL STUDIES/ANALYSIS- CHEMICAL/BIOLOGICAL | $71K | IRISYS, LLC |
| Jan 6, 2016 | NIH | NIH N02 IGF::OT::IGF SPECIAL STUDIES/ANALYSIS- CHEMICAL/BIOLOGICAL | $156K | IRISYS, LLC |
| Oct 30, 2015 | NIH | NIH N02 IGF::OT::IGF PRODUCTION OF 650 BOTTLES OF TETRAHYDROURIDINE POWDER, HHSN261201200009I/HHSN26100009, DTP-16-003, DEVELOPMENT AND MANUFACTURE OF ORAL AND TOPICAL DOSAGE FORMS, PRBPERIOD OF PERFORMANCE | $67K | IRISYS, LLC |
| Jul 1, 2010 | NIH | NIH N02 TAS::75 0849::TAS DEVELOPMENT AND MANUFACTURE OF ORAL AND TOOPICAL DOSAGE FORMS | $327K | IRISYS, LLC |
| Jul 1, 2010 | NIH | NIH N02 TAS::75 0849::TAS DEVELOPMENT AND MANUFACTURE OF ORAL AND TOOPICAL DOSAGE FORMS | $145K | IRISYS, LLC |
| Jul 1, 2010 | NIH | NIH N01 TAS::75 0849::TAS DEVELOPMENT AND MANUFACTURE OF ORAL AND TOOPICAL DOSAGE FORMS | $310K | IRISYS, LLC |
| Jul 1, 2010 | NIH | NIH N02 TAS::75 0849::TAS DEVELOPMENT AND MANUFACTURE OF ORAL AND TOOPICAL DOSAGE FORMS | $283K | IRISYS, LLC |
| Jul 1, 2010 | NIH | NIH N02 TAS::75 0849::TAS DEVELOPMENT AND MANUFACTURE OF ORAL AND TOOPICAL DOSAGE FORMS | $130K | IRISYS, LLC |
| Jul 1, 2010 | NIH | NIH N02 TAS::75 0849::TAS DEVELOPMENT AND MANUFACTURE OF ORAL AND TOOPICAL DOSAGE FORMS | $62K | IRISYS, LLC |
Peer ranks
Federal funding#41
Awards as PI#1
Patents#27
Companies
- IRISYS, LLCLinked by awards
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.